Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
19 hedge funds and large institutions have $798K invested in Evoke Pharma in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 7 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
4.38% less ownership
Funds ownership: 9.88% → 5.5% (-4.4%)
14% less funds holding
Funds holding: 22 → 19 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
69% less capital invested
Capital invested by funds: $2.56M → $798K (-$1.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$58.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$40.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.9K |
| 4 |
VF
Virtu Financial
New York
|
+$19.7K |
| 5 |
Renaissance Technologies
New York
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$283K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$139K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$65K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$24.2K |
| 5 |
SIM
Spark Investment Management
New York
|
-$24K |
EVOK Hedge Fund Activity: Q2 2019 in Review
19 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2019, worth a combined $798K — down 69% from $2.56M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of EVOK and 4 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Geode Capital Management, adding an estimated $58.1K. The largest seller was Vanguard Group, cutting an estimated $283K.
- 19 institutional investors held Evoke Pharma (EVOK) as of Q2 2019, down from 22 in Q1 2019.
- Funds reported $798K of Evoke Pharma stock for Q2 2019, down 69% quarter-over-quarter.
- 4 funds opened new Evoke Pharma positions in Q2 2019 and 7 closed out, a net change of -3 holders.
- The largest Evoke Pharma buyer in Q2 2019 was Geode Capital Management, an estimated $58.1K added.
- The largest Evoke Pharma seller in Q2 2019 was Vanguard Group, an estimated $283K sold.
Based on aggregated 13F filings for Q2 2019.